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Summary
Systemic amyloidosis is a heterogeneous group of dis-
eases associated with protein misfolding into insoluble be-
ta-sheet rich structures that deposit extracellularly in differ-
ent organs, eventually compromising their function. There
are more than 30 different proteins, known to be amy-
loidogenic with “light chain” (AL)-amyloidosis being the
most common type, followed by transthyretin (ATTR)-, and
amyloid protein A (AA)-amyloidosis. Systemic amyloido-
sis is a rare disease with an incidence of around 10 pa-
tients in 1 million inhabitants. Recently several new ther-
apeutic options have been developed for subgroups of
amyloidosis patients, and the introduction of novel thera-
pies for plasma cell myeloma has led to an increase in
the therapeutic armamentarium for plasma cell disorders,
including AL amyloidosis. Among them, proteasome in-
hibitors, immunomodulatory agents (-imids), and mono-
clonal antibodies have been successfully introduced into
clinical practice. Still, high-quality data from randomised
controlled trials regarding the benefit of these cost-inten-
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sive drugs in AL amyloidosis are widely lacking, and due
to the rarity of the disease many physicians will not gain
routine experience in the management of these frail pa-
tients. The diagnosis of AL amyloidosis relies on a close
collaboration between clinicians, pathologists, imaging ex-
perts, and sometimes geneticists. Diagnosis and treat-
ment options in this complex disorder should be discussed
in dedicated multidisciplinary boards.
In January 2020, the first meeting of the Swiss Amyloido-
sis Network took place in Zurich, Switzerland. One aim of
this meeting was to establish a consensus guideline re-
garding the diagnostic work-up and the treatment recom-
mendations for systemic amyloidosis tailored to the Swiss
health care system. Forty-five participants from different
fields in medicine discussed many aspects of amyloidosis.
These are the Swiss Amyloidosis Network recommenda-
tions which focus on diagnostic work-up and treatment of
AL-amyloidosis.
Keywords: AL amyloidosis, Swiss Amyloidosis Network,
expert recommendation, diagnostic work-up and treat-
ment
Introduction
Systemic amyloidosis is a heterogeneous group of diseases
associated with protein misfolding into insoluble beta-
sheet rich structures that deposit extracellularly in different
organs, eventually compromising their function. There are
more than 30 different proteins known to be amyloido-
genic in vivo with “light chain” (AL)-amyloidosis being
the most common type, followed by transthyretin (ATTR)-
and amyloid protein A (AA)-amyloidosis [1]. Systemic
amyloidosis is a rare disease with an incidence of around
10 patients in 1 million inhabitants [2, 3]. Recently several
new therapeutic options have been developed for sub-
groups of amyloidosis patients, and the introduction of
novel therapies for plasma cell myeloma has led to an in-
crease in the therapeutic armamentarium for plasma cell
disorders, including AL-amyloidosis. Among them, pro-
teasome inhibitors, immunomodulatory agents (“-imids”)
and monoclonal antibodies have been successfully intro-
duced into clinical practice.
Still, high-quality data from randomised controlled trials
regarding the benefit of these cost-intensive drugs in AL-
amyloidosis are widely lacking, and owing to the rarity
of the disease many physicians will not gain routine ex-
perience in the management of these frail patients. The
diagnosis of AL-amyloidosis relies on a close collabora-
tion between clinicians, pathologists, imaging experts and
sometimes geneticists. Diagnosis and treatment options in
this complex disorder should be discussed by dedicated
multidisciplinary boards. The current Swiss expert recom-
mendations aim at helping decision making for teams car-
ing for patients with AL-amyloidosis.
In January 2020, the first meeting of the Swiss Amyloido-
sis Network (SAN) took place in Zurich, Switzerland. One
aim of this meeting was to establish a consensus guideline
regarding the diagnostic work-up and treatment recom-
mendations for systemic amyloidosis, tailored to the Swiss
healthcare system. Forty-five participants from haematol-
ogy, oncology, cardiology, nephrology, neurology, hepatol-
ogy, nuclear medicine and pathology, as well as geneticists
and scientists engaged in basic research, discussed many
aspects of amyloidosis. The five University Hospitals of
Basel, Bern, Geneva, Lausanne and Zurich, as well as the
five large tertiary hospitals Bellinzona, Chur, Luzern, St
Gallen and City Hospital Waid and Triemli Zurich were
represented.
These Swiss Amyloidosis Network recommendations fo-
cus on diagnostic work-up and treatment of AL-amyloido-
sis.
Clinical considerations
The precursor proteins of AL-amyloidosis are monoclonal
immunoglobulin light chains, deriving from an underlying
plasma cell neoplasm, including plasma cell myeloma or,
less commonly, B-cell lymphoma. The tumour load, i.e.,
the degree of bone marrow infiltration by neoplastic cells,
does not necessarily correlate with AL load and is often
low. Due to the comparatively low plasma cell burden, the
free light chains measurable in the serum are often only
slightly elevated. Not all monoclonal light chains are amy-
loidogenic, and there is a predominance of lambda over
kappa light chains in AL-amyloidosis [4]. In about 50%
of amyloidosis patients, the affected monoclonal plasma
cells carry a translocation t(11;14), which is only present
in about 15% of plasma cell myeloma patients [5]. Organ
dysfunction is a result of amyloid deposition in the tis-
sue, but there is evidence of direct toxicity of the free-light
chain, for example on cell metabolism and cardiac function
[6].
One of the main limitations for effective treatment is the
delay between first symptoms and the diagnosis of AL-
amyloidosis. First symptoms of AL-amyloidosis are often
nonspecific, and without a high level of awareness most
patients will be diagnosed at an advanced stage, where
treatment is usually more difficult and less effective [7].
Therefore, it is essential to make the diagnosis of AL-
amyloidosis as early as possible. The majority of AL-
amyloidosis patients have abnormal free light chain (FLC)
studies with elevated dFLC (difference involved minus un-
involved FLC) levels that steadily increase over time for
years prior to diagnosis [8, 9]. This is the reason why the
SAN recommends regular screening of patients with mono-
clonal gammopathy of undetermined significance (MGUS)
and smouldering plasma cell myeloma according to Inter-
national Myeloma Working Group (IMWG) 2010 guide-
lines [10] (initial follow up after 6 months, if stable annu-
ally) for the presence of amyloid cardiomyopathy (elevated
N-terminal pro-B-type natriuretic peptide [NTproBNP])
[11] and nephropathy (especially albuminuria) or any oth-
er clinical signs of amyloidosis. In the event of abnormal
findings, work-up for systemic amyloidosis should be ini-
tiated. Routine amyloid staining of the bone marrow is
not indicated in patients with MGUS or multiple myeloma
without suspicion of AL-amyloidosis [12].
The most commonly involved organs are heart, kidneys,
nervous system, soft tissue and liver [13, 14]. Suspicion
of a diagnosis of AL-amyloidosis should be raised in pa-
tients with MGUS or plasma cell myeloma who present
with heart failure with preserved ejection fraction (HF-
pEF), albuminuria, unexplained weight loss, autonomous
and peripheral neuropathy (specifically small fibre neu-
ropathy), hepatomegaly, chronic diarrhoea or carpal tunnel
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syndrome, especially if bilateral. A history of spontaneous
periorbital bruising (“raccoon eyes”), macroglossia or
swelling of the shoulder (shoulder pad sign) are pathogno-
monic, but late, signs for the disease and should prompt a
work-up for systemic AL-amyloidosis [4] (table 1)
Localised AL-amyloidosis
AL-amyloidosis may affect one single site [15, 16]. In lo-
calised amyloidosis, a monoclonal component in plasma is
usually absent. It is hypothesised that a B-cell / plasma cell
clone develops at a site of chronic inflammation, produc-
ing amyloidogenic light chains, with additional local fac-
tors favouring their deposition as insoluble amyloid. Typ-
ical sites for localised amyloidosis are the skin, the upper
airways in particular and the respiratory tract in general,
the genital and urinary system, the eye, the lymph nodes
and the gastrointestinal tract [17]. Localised amyloidosis
almost never progresses to a systemic form, and its prog-
nosis is excellent. The treatment of this “amyloidoma” is
surgical excision when possible.
The SAN recommends a thorough work-up for patients
with suspected localised amyloidosis to exclude systemic
involvement. This includes a search for monoclonal free
light chains / monoclonal protein by electrophoresis with
immunofixation of serum and urine, and nephelometric
measurement of serum free light chain levels. In the event
of abnormalities, a bone marrow biopsy examination with
Congo red staining, Congo red staining of an abdominal
fat biopsy, as well as work up for cardiac and renal in-
volvement (NTproBNP, echocardiography including analy-
sis of longitudinal left ventricular deformation [“strain”]
and/or cardiac magnetic resonance imaging [MRI]), as
well as determination of albumin/creatinine and protein/
creatinine ratios) should be performed. The SAN recom-
mends follow-up of these patients annually, at least initial-
ly, in order to detect local reoccurrence [18].
Table 1: Organ involvement.
Organ Occurrence Clinical Symptoms Biomarkers Diagnostics
Heart 75% Heart failure
Arrhythmia
Syncope
Sudden cardiac death
NTproBNP
Troponin T
ECG: low voltage, pseudoinfarction
pattern, atrial fibrillation
Echocardiography: biventricular wall
thickening, thickening of the interatrial
septum, pericardial effusion, preserved
ejection fraction with diastolic dysfunc-
tion including signs of increased filling
pressures or atrial enlargement, “apical
sparing” pattern by global longitudinal
peak strain or speckle tracking
MRI: thickening of the myocardium,
atrial enlargement, late gadolinium en-
hancement, increased native T1, extra-
cellular volume and T2 mapping. Peri-
cardial and pleural effusion
Kidney 50–70% Oedema
Foamy urine
Proteinuria/albuminuria
Estimated glomerular filtration rate
24-hour urine collection
Spot urine
Nerve involvement 35%
Presenting symptoms:
7.5%
Small-fibre neuropathy:
paraesthesia, numbness,
pain
All-fibre neuropathy: at later
stages
Autonomic: gastroparesis,
bladder/bowel dysfunction,
orthostatic hypotension, va-
somotor symptoms, hyper-
hidrosis, sicca syndrome,
erectile dysfunction
Bilateral carpal tunnel syn-
drome
– Nerve conduction study (normal if only
small fibres involved)
Electrophysiological autonomic tests:
R-R interval, sympathetic skin reflex
Sudoscan®, laser evoked potentials if
available
Schellong test
Skin biopsy (small fibre neuropathy)
Nerve biopsy if large fibres involved
and no other organ accessible to biop-
sy
Tissue biopsy if surgery is performed
Gastrointestinal involvement 10% Diarrhoea
Constipation
Nausea
Vomiting
Weight loss
– Colonoscopy
Gastroscopy
Liver 20% – Alkaline phosphatase Hepatomegaly (ultrasound)
If liver biopsy is performed it should be
done as a transjugular biopsy and not
percoutaneously owing to the in-
creased bleeding risk
Skin / soft tissue 10–15% Periorbital purpura (racoon
eyes)
Macroglossia
Swelling of the shoulder
pad (“Shoulder pad sign”)
– Clinical examination
Bleeding diathesis – Easy bruising / sponta-
neous bleeding due to ac-
quired factor X deficiency /
acquired Von Willebrand
disease, amyloid infiltration
in blood vessels
Coagulation factor X
von Willebrand factor (functional)
Quick, activated partial thromboplastin time
Coagulation testing
MRI = magnetic resonance imaging; NTproBNP = N-terminal pro-B-type natriuretic peptide
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Diagnostic work-up
When a patient presents with clinical symptoms compat-
ible with AL-amyloidosis, a thorough work-up for mon-
oclonal gammopathy must be performed including serum
protein electrophoresis, serum FLCs and immunofixation
of the serum and urine. In the presence of a monoclonal
gammopathy, especially if a pathological FLC ratio is pre-
sent, a tissue sample for amyloid detection with Congo
red staining and immunohistochemistry or mass spectrom-
etry is required to establish the diagnosis and to allow for
subtyping of the amyloid. In the published literature, an
abdominal fat tissue aspirate together with a bone mar-
row biopsy of at least 1.5 cm length is recommended, and
should secure the diagnosis in 80% of patients with AL-
amyloidosis [19]. Minor salivary gland biopsy is also sen-
sitive in the detection of amyloid (68.4%) [20].
At the SAN meeting, experts agreed that this high yield of
positive fat pad aspirates is true for large amyloidosis re-
ferral centres, where fat pad aspiration is the recommended
first option to search for amyloid deposits, but cannot be
achieved by smaller centres and might reflect differences
in sampling and processing of the material. Furthermore,
fat pad aspirates are helpful for detecting amyloid by Con-
go red staining, but the material is not suitable for immuno-
histochemistry, which is needed to type the amyloid and
is performed almost exclusively on tissue biopsies. Immu-
noelectron microscopy or mass spectrometry can be suc-
cessfully performed on fat pad aspirates, but are currently
not available in Switzerland. The SAN recommends fat pad
biopsies, minor salivary gland or deep rectum biopsies for
diagnosis. If a patient has had a tissue biopsy for other rea-
sons (e.g., polypectomy during a colonoscopy), these sam-
ples can be retrospectively screened for amyloid by Con-
go red staining. If a bone marrow biopsy is performed in a
work-up for MGUS in a patient with suspicion of AL-amy-
loidosis, it must be thoroughly evaluated for amyloid de-
position. If all samples stain negative for amyloid and sus-
picion remains high, an organ biopsy should be performed
[1]. We should keep in mind that, owing to vascular amy-
loid deposits and possible factor X deficiency due to ad-
sorption to amyloid fibrils [21, 22], bleeding risk can be in-
creased. Given the high bleeding risk, liver biopsy should
be performed only through a venous trans-jugular access.
The presence of a plasma cell neoplasm in combination
with histological documentation of amyloid by Congo red
staining alone does not allow the diagnosis of AL-amyloi-
dosis. Amyloid typing is crucial, as other forms of amy-
loidosis are increasingly recognised to be quite common
in the elderly population, especially ATTR-amyloidosis. In
these elderly patients, plasma cell dyscrasia might be an in-
nocent bystander unrelated to amyloidosis [23]. As a mat-
ter of fact, patients with ATTR-amyloidosis have a very
high incidence of concomitant MGUS (23%) [24]. No-
tably, studies have demonstrated the high diagnostic accu-
racy of bone scintigraphy in the non-invasive assessment
of cardiac ATTR-amyloidosis [25]. However, in the pres-
ence of MGUS, bone scintigraphy alone cannot be used to
rule out AL-amyloidosis and a tissue biopsy is mandatory
[26].
The SAN concludes that amyloid typing is crucial to es-
tablish the diagnosis. Mass spectrometry is considered the
gold standard [1]. However, in Switzerland mass spectrom-
etry is not available in this context and typing is main-
ly done by means of immunohistochemistry. Immunohis-
tochemistry is challenging, and one Swiss centre, the
Institute of Pathology, University Hospital Basel, has es-
tablished an immunohistochemistry panel with non-com-
mercially available antibodies for amyloid typing [27],
similar to the ones used by the German reference pathol-
ogy laboratory in Kiel. Equivocal cases can be sent for a
second opinion to a reference centre outside of Switzerland
(for example, to the German reference pathology laborato-
ry in Kiel). Mass spectrometry can be performed in Pavia,
Italy, although the logistical obstacles (e.g., transport, cost
coverage by the Swiss health insurance) can delay diagno-
sis.
The diagnostic work-up is summarised in figure 1.
As soon as the diagnosis of AL-amyloidosis is established,
the general health status of the patient, the biology of the
disease and the extent of organ involvement have to be de-
termined. The SAN recommends a structured baseline as-
sessment for all patients as presented in table 2.
Prognostic factors
The global prognosis of patients suffering from AL-amy-
loidosis has improved over time as a result of better ther-
apeutic options targeting plasma cells [28]. Nevertheless,
early mortality remains a challenge [29, 30]. The clinical
course of patients with AL-amyloidosis depends mainly on
the type and extent of the organ involvement. Cardiac in-
volvement is the main determinant for adverse outcome
and prognostic models have implemented cardiac biomark-
ers such as troponin T or troponin I, NTproBNP and BNP,
as powerful predictors at diagnosis for survival duration
and relapse [31]. In Switzerland, centres mainly use the re-
vised Mayo risk prediction model of 2012 to predict out-
come and adapt therapy, and a NTproBNP cut-off of >8500
ng/l to identify a subset of patient with a particularly poor
outcome [32] (table 3). In patients with predominantly re-
nal involvement, a distinct staging system can help predict
the renal outcome [33] (table 4).
Additional patient and disease characteristics associated
with poor outcome and survival include systolic blood
pressure <100 mm Hg, intraventricular septum thickness
>15 mm, myocardial tissue characterisation by cardiac
MRI (transmural extent of late gadolinium enhancement
[34], extracellular volume >45% by T1 mapping [35] or
evidence of myocardial oedema by T2 mapping [36]), clas-
sical myeloma end-organ damage (hypercalcaemia, renal
insufficiency, anaemia, bone lesions) and/or bone marrow
plasma cells ≥10%, >50% del17p in interphase fluores-
cence in situ hybridisation (iFISH), immunoparesis, pres-
ence of circulating plasma cells and elevated lactate dehy-
drogenase [37–41].
Patient and disease characteristics associated with better
outcome and survival are eligibility for high-dose mel-
phalan and autologous stem cell transplantation (ASCT)
[42, 43], low and therefore non-evaluable difference of in-
volved and uninvolved free light chains (dFLC) at diagno-
sis (<50 mg/l) [44], depth of haematological response after
induction therapy (≥very good partial remission, VGPR)
and depth of organ response [45].
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Figure 1: Flow chart of the diagnostic work-up.
Table 2: Baseline evaluation.
General Haematology Cardiology Nephrology Neurology Gastroenterology
Laboratory work-
up
CRP
TSH, fT4
Protein
Albumin
Vitamin B12
Hepatitis A+B
HIV
Bloodcount with micro-
scopic differentiation
Reticulocytes
INR, aPTT
Coagulation factor X
protein electrophoresis
immunfixation*
serum free light chain
levels
Immunoglobulins
Type and screen†
NTproBNP Troponin T Creatinine
Electrolytes
Urine sediment
Protein/creatinine‡
Albumin/creatinine‡
optl 24-hour urine
- protein
- albumin
- immunofixation
(Anti-MAG antibodies) Liver parameters
Cholestatic parameters
Clinical examina-
tion
Macroglossia?
Racoon eyes?
Shoulder pad sign?
Nail changes?
Bruises Blood pressure
Heart rate
Schellong test
Peripheral oedema
Signs of heart failure
ECG
ECG Holter
Spiroergometry
Screening for polyneu-
ropathy (sensitivity to
light touch, pin-prick and
temperature, vibration
and position sense, deep
tendon reflexes)
Hepatomegaly
Splenomegaly
Imaging – Low-dose CT if osteoly-
sis is suspected
optl whole body MRI
Echocardiography
optl MRI
optl kidney ultrasound NCS and neurophysio-
logical tests for small
nerve fibres if screening
is positive
Abdominal ultrasound
optl fibroscan
optl endoscopy
Intervention Bone marrow tap
- cytology
- histology including
Congo red stain
- flowcytometry (mini-
mal residual disease if
possible)
- FISH
For specific questions
(e.g., differentiation AT-
TR vs AL) Endomyocar-
dial biopsy
aPTT = activated partial thromboplastin time; CRP = C-reactive protein; CT = computed tomography; FISH = fluorescence in situ hybridisation; fT4 = free thyroxine; HIV = human
immunodeficiency virus; INR = international normalised ratio; MAG = myelin associated glycoprotein; MRI = magnetic resonance imaging; NCS = nerve conduction studies;
NTproBNP = N-terminal pro-B-type natriuretic peptide; optl = optional; TSH = thyroid stimulating hormone * Serum and urine; † especially prior to daratumumab; ‡ spot urine
Scintigraphy for ATTR-amyloidosis only (not necessary in work-up for AL-amyloidosis)
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Predictive markers: Baseline iFISH can predict the effica-
cy of the first-line therapy in AL-amyloidosis. Transloca-
tion t(11;14) is detected in roughly half of the patients and
is associated with lower haematological event-free survival
and overall survival in patients treated with bortezomib
[46, 47]. However, treatment with high-dose melphalan +
ASCT is able to reverse the negative impact of t(11;14) on
overall survival [48]. Conversely, gain of 1q is an indepen-
dent adverse prognostic factor in AL-amyloidosis patients
treated with melphalan [49]. In the bone marrow work-up,
the SAN recommends cytogenetic analysis including iFISH
+/− aCGH (array-based comparative genomic hybridis-
ation) as well as immunophenotyping at baseline, iFISH
should be performed in a CD138+ plasma cell enriched
sample.
Response assessment
In AL-amyloidosis, one has to differentiate between
haematological response and organ response. The haema-
tological response measures the effect of the plasma cell-
directed therapy, and is subdivided into four response cate-
gories based on the changes in dFLC and serum and urine
electrophoresis with immunofixation (table 5). The deeper
the response the better the outcome, but obtaining at least
a VGPR should be the goal of every treatment regimen
(overall survival 80–90% after 3 years) [50]. The effective-
ness of therapy should be assessed regularly. As FLC have
a short half-life (hours), response is measurable shortly af-
ter treatment initiation and the treatment regimen should
be changed rapidly if inefficient (decrease in dFLC <50%
after 2–3 cycles). Organ response is the ultimate goal of
therapy but is usually delayed and can take as long as 9.4
months (heart), 6 months (kidney) and 6.1 months (liver)
after obtaining a complete haematological response (table
5) [51]. The SAN recommends a structured assessment and
documentation of the haematological response and of the
organ response at least every 3 months. During immuno-
/chemotherapy haematologialc response (dFLC) should be
determined at least on day one of every treatment cycle and
at the end of treatment.
Therapeutic recommendations
Therapy is indicated in all patients with confirmed sys-
temic AL-amyloidosis. There are few exceptions in pa-
tients with a coincidental finding of amyloid deposits in
tissue samples with absence of systemic organ involve-
ment. These subjects with asymptomatic amyloid deposits
do not require treatment, but should be carefully followed
up to detect potential organ dysfunction in a timely manner
[9]. The goal of treatment is to suppress the malignant plas-
ma cell clone in order to prevent further FLC production
and deposition of amyloid in the already altered organs.
Table 3: Staging of AL-amyloidosis (revised Mayo Model 2012, Kumar et al., JCO 2012 [31]).
Risk factors Difference between involved and uninvolved serum free light chains >180 mg/l
Cardiac troponin T ≥25 ng/l
NTproBNP ≥1800 ng/l
Score (1 point per risk factor) Stage Median survival (months)
0 I 94.1
1 II 40.3
2 III 14.0
3 IV 5.8
NTproBNP = N-terminal pro-B-type natriuretic peptide
Table 4: Renal staging system (Palladini et al., Blood 2014 [33]).
Risk factors Estimated glomerular filtration rate <50 ml/min
Proteinuria >5 g/24h
Score (1 point per risk factor) Stage 2-year risk for dialysis
0 I 0–3%
1 II 11–25%
2 III 60–75%
Table 5: Response criteria (Palladini et al., JCO 2012 [50]).
Haematological
Complete response (CR) Negative serum and urine immunofixation, normal serum FLC ratio
Very good partial response (VGPR) dFLC <40 mg/l
Partial response (PR) Reduction of dFLC ≥50%
No response Reduction of dFLC <50%
Organ response parameters
Non-responder ≤30% reduction in organ response parameters:
- Cardiac: NTproBNP
- Renal: proteinuria
- Hepatic: alkaline phosphatase
Partial responders 31–60% reduction
Very good partial responders >60%
Complete responders Nadir NTproBNP ≤400 ng/l
Nadir proteinuria ≤200 mg/24h
Nadir alkaline phosphatase ≤2 × upper limit of reference range
dFLC = difference involved minus uninvolved FLC; FLC = free light chain; NTproBNP = N-terminal pro-B-type natriuretic peptide
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Although the pathological plasma cell clone is generally
sensitive to current treatment approaches, the therapeutic
agents are often poorly tolerated and morbidity and mor-
tality, especially at the beginning of treatment, can be sig-
nificant. Frequent adjustment of the therapeutic regimen is
common and symptom management is an integral part of
therapy. Therefore, the SAN recommends a multidiscipli-
nary approach involving amyloidosis specialists from dif-
ferent fields in internal medicine to make treatment deci-
sions, even in experienced centres [1].
The available clinical data to drive treatment decisions in
AL-amyloidosis consist mainly of phase II studies, retro-
spective comparisons and case series. The treatment proto-
cols (see figs 2 and 3) are similar to those used for plas-
ma cell myeloma, although dose adaptations are common
to allow better tolerability. The choice of the initial therapy
is also driven by the labelling and reimbursement of cost
by the Swiss healthcare insurances, as there are no drugs
specifically approved for AL-amyloidosis in the absence of
an underlying multiple myeloma.
High-dose therapy and autologous stem cell transplan-
tation (ASCT)
One of the most important treatment decisions is whether
a given patient is “fit” enough to tolerate high-dose mel-
phalan + ASCT. Historically, transplant-related mortality
in less stringently selected patients with AL-amyloidosis
was as high as 24%, mainly because of the inclusion of pa-
tients with advanced cardiac involvement [52]. As a con-
sequence, many centres have adapted their selection crite-
ria for high-dose melphalan + ASCT with special attention
Figure 2: First-line treatment.
Figure 3: Treatment in the relapse/refractory setting.
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to sufficient cardiac reserve [53]. Selection criteria for AS-
CT in AL amyloidosis have undergone significant mod-
ification over time [54]. The SAN experts agreed on the
Onkopedia Guidelines established by the University Hos-
pital Heidelberg as selection criteria for patients eligible
for ASCT (table 6). Further, troponin T levels >60 ng/l
are associated with adverse outcome as expected day-100
mortality rate is 25% or higher. Therefore, these patients
should not be considered viable candidates for ASCT [55].
With this more restrictive patient selection, only 25% of
patients are eligible for high-dose melphalan + ASCT. Pro-
vided the procedure is performed in an experienced centre,
transplant-related mortality is significantly reduced to
<5%, with a favourable outcome especially in patients who
achieve a complete response (3 year overall survival 84%
vs 59% in the non-transplant group). If high-dose melpha-
lan + ASCT is used, the SAN recommends a bortezomib-
based induction therapy prior to stem cell collection, al-
though the data to support this approach are scarce [53,
56]. Further, high-dose melphalan + ASCT should only
be used in patients fit enough for full dose melphalan, as
dose reduction is associated with adverse outcome (low-
er complete response rates, higher transplant-related mor-
tality, lower survival rate) [57]. Induction therapy allows
an immediate start of therapy, which is important since the
prompt clearance of the toxic circulating light chains will
potentially improve patient outcome and will reveal valu-
able information with regard to physical fitness prior to
the more strenuous ASCT. In patients with polyneuropathy,
the SAN considers skipping induction to avoid addition-
al bortezomib-induced neurotoxicity. The SAN agrees that
high-dose melphalan + ASCT should only be performed at
centres with experience in the treatment of AL-amyloidosis
as it has been shown that outcome is better in centres per-
forming more than four AL transplants a year [57].
Proteasome inhibitors
The introduction of proteasome inhibitors, especially
bortezomib, has played a decisive role in the treatment of
AL-amyloidosis and has significantly contributed to im-
provement in outcome of AL-amyloidosis patients. It is
used as an induction regimen prior to high-dose melphalan
+ ASCT in combination with dexamethasone and cy-
clophosphamide (CyBorD) with haematological response
rates between 50 and 70% [53, 58]. Preliminary data of a
prospective randomised controlled phase III trial compar-
ing melphalan and dexamethasone with bortezomib, mel-
phalan and dexamethasone (BMDex) in non-transplant-
eligible patients showed an improved haematological
response in the BMDex group (84% vs 57%, p = 0.005)
[59].
Table 6: Selection criteria for autologous stem cell transplantation
(Onkopedia Leitlinien September 2017).
Age <65–70 years
Eastern Cooperative Oncology Group performance status score <2
Revised Mayo cardiac stage <3, New York Heart Association class
<III
Systolic blood pressure >90 mm Hg
No cardiac related effusions
Creatinine clearance >30 ml/min
The dose and frequency of bortezomib administration var-
ied in the different studies, the most commonly used dos-
ing being 1.3 mg/ m2 once or twice weekly. In patients
with cardiac involvement, therapy with bortezomib might
worsen orthostatic dysregulation, especially in high risk
patients (revised Mayo stage III with NTproBNP levels
>8500 ng/l and/or New York Hear Association [NYHA]
class III) [32] To improve tolerability of therapy the SAN
recommends starting with 1 mg/m2 once weekly in patients
with cardiac involvement (revised Mayo stage III), with
a dose increase if well tolerated. Bortezomib should be
administered subcutaneously and not be used in patients
suffering from neuropathy (peripheral and autonomic). In
transplant-eligible patients, the SAN recommends the non-
melphalan containing regimen CyBorD as an induction
regimen prior to high-dose melphalan + ASCT to reduce
stem cell toxicity. In non-transplant eligible patients the
SAN prefers the combination of bortezomib and melphalan
plus dexamethasone (BMDex) to overcome the previously
discussed lower response rates associated with doublet
therapy in patients with t(11;14) or gain of 1q [60, 61].
Carfilzomib, a second-generation proteasome inhibitor, is
a standard agent for patients with plasma cell myeloma. In
a multicentre phase I/II trial in patients with AL-amyloi-
dosis, the overall haematological response rate was 63% in
these relapsed/refractory patients, but all-cause Common
Terminology Criteria for Adverse Events (CTCAE) grade
3 (severe) and 4 (life-threatening) where as high as 71%
with several cardiac or pulmonary events [62]. Therefore,
the SAN recommends using carfilzomib only in the absence
of other options and only in patients with AL-amyloidosis
without cardiac involvement.
Ixazomib, an oral proteasome inhibitor, is currently ap-
proved in Switzerland in combination with lenalidomide
and dexamethasone as a second and third line treatment
in patients with plasma cell myeloma. In 2014, a phase I/
II study demonstrating a haematological response rate of
52% with less neurotoxicity when compared with borte-
zomib led to the US Food and Drug Administration (FDA)
approval of ixazomib and dexamethasone in AL-amyloi-
dosis patients [63]. In a phase III trial (TOURMALINE-
AL1) [64], ixazomib was studied in previously treated
AL-amyloidosis patients in combination with dexametha-
sone and did not demonstrate significant improvement of
haematological response compared with standard therapy,
which led to the discontinuation of the study. Ixazomib +
dexamethasone led to an overall response rate of 53% vs
51% in the physician’s choice group. The majority of pa-
tients (71 of 83) in the control arm where treated with ei-
ther melphalan + dexamethasone or lenalidomide + dex-
amethasone. Both combinations are effective, with
haematological response rates between 51% and76% (mel-
phalan + dexamethasone), and 41% and 67% (lenalido-
mide + dexamethasone), so this result is not surprising [65,
66]. Ixazomib was well tolerated in the trial population and
remains an option in patients with neuropathy if a protea-
some inhibitor is the agent of choice.
Monoclonal antibodies
Daratumumab, a monoclonal antibody targeting CD38, ap-
pears to be highly effective in the treatment of AL-amyloi-
dosis patients [67–69]. The antibody shows rapid and deep
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response rates with an excellent tolerability profile, even
in stage IV patients. So far, there were only reports from
retrospective case series, all reporting haematological re-
sponse rates between 63% and 83% in a generally pretreat-
ed patient population [70, 71]. A phase III trial compar-
ing daratumumab -CyBorD with CyBorD enrolled patients
with daratumumab given subcutaneously (NCT03201965).
Results have been presented at EHA 2020, and show high-
er rates of overall haematological response (92% vs 77%)
in the experimental arm and very good partial response
or better (≥VGPR 79% vs 49%). The 6-month cardiac re-
sponse rate was 42% for daratumumab -CyBorD and 22%
for CyBorD (p = 0.0029); 6-month renal response rates
were 54% and 27%, respectively (p <0.0001) [72].
Daratumumab commonly causes profound hypogamma-
globulinaemia and increases susceptibility for infections,
including pneumonia. Intravenous or subcutaneous im-
munoglobulin substitution should be established in pa-
tients with infectious complications, and vaccination
against invasive pneumococcal disease and influenza must
be given prior to treatment initiation [67]. With respect
to these precautionary measures, the SAN recommends
implementation of daratumumab treatment early in the
course of the disease, as monotherapy or in combination
with a bortezomib-based regimen. In Switzerland, daratu-
mumab in combination with bortezomib, melphalan and
prednisone is approved for first-line treatment of trans-
plant-ineligible patients with plasma cell myeloma. This is
valuable in negotiations with the health insurance compa-
ny to obtain cost coverage.
For elotuzumab, an anti-SLAM-F7 antibody, there are only
sporadic data in patients with AL-amyloidosis. Elotuzum-
ab cannot be recommended as a standard treatment for AL-
amyloidosis as yet.
Alkylating agents
Despite the abundance of new effective treatment options,
alkylating agents such as melphalan, cyclophosphamide or
bendamustine are still therapeutic options for AL-amyloi-
dosis. Haematological response rates with melphalan can
be as high as 76% (combination with dexamethasone 40
mg daily for 4 days) with good tolerability [66]. Time to re-
sponse is usually longer than with newer agents. It is most
suitable for elderly patients with revised Mayo stage I/II,
where the need to start immediate treatment is lower. Cy-
clophosphamide is mainly used in combination with borte-
zomib and dexamethasone (CyBorD) as an induction regi-
men prior to high-dose melphalan + ASCT and upfront in
transplant-ineligible patients as discussed above. Oral ad-
ministration once weekly (300 mg/m2) is a typical mode
of application. Bendamustine with or without rituximab is
mainly used in IgM-AL-amyloidosis, where the patholog-
ical cell clone is usually at a B-cell maturation step (e.g.,
IgM MGUS, Waldenström's macroglobulinaemia, lympho-
plasmocytic lymphoma, marginal zone lymphoma, chronic
lymphatic lymphoma). It has proven to be reasonably well
tolerated and effective with haematological response rates
of 57% [73].
Immunomodulatory drugs
Immunomodulators such as lenalidomide and pomalido-
mide are given orally, usually as combination therapies
with corticosteroids (“doublets”) and have shown efficacy
mainly in case series of pretreated AL-amyloidosis pa-
tients. Lenalidomide combined with dexamethasone shows
haematological response rates of 41–67% [63, 64], without
further improvement when used as a “triplets” for example
together with melphalan (overall response rate 50–58%) or
cyclophosphamide (overall response rate 46–60%). Poma-
lidomide has been combined with dexamethasone, show-
ing haematological response rates of 48–60% [74]. Unlike
in plasma cell myeloma, the tolerability of these drugs in
AL-amyloidosis is limited, and the discontinuation rate is
high (>40%). The SAN experts agree on mandatory initial
dose reductions. Typical initial dose levels for lenalido-
mide are 10 mg/d (5–15 mg) on days 1 to day 21, and for
pomalidomide 2 mg (1–4 mg) on days 1 to 21. Lenalido-
mide and pomalidomide have several haematological and
non-haematological toxicities, including neutropenia, in-
fections, worsening of kidney function and a rise of NT-
pro BNP levels [75]. Both agents are legitimate second-
line agents when used with caution in patients with cardiac
and/or renal involvement.
Venetoclax
Venetoclax is a B cell lymphoma 2 (BCL-2) inhibitor ac-
tive in plasma cell myeloma, particularly those patients
harbouring t(11;14) associated with high BCL-2 expres-
sion. Approximately 50% of patients with AL-amyloidosis
have t (11;14), making venetoclax a suitable agent to con-
sider in this rare disease. So far, limited case series of
mostly heavily pretreated patients confirmed efficacy as
single agent and in combination with an acceptable safety
profile. Further studies are warranted [76–78].
Supportive treatment
Symptom management is an integral part of therapy. It
includes anti-infective strategies, diuretics, antiarrhythmic
drugs, pain medication and agents that control bowel dys-
function.
Anti-infectious strategies: Prior to treatment initiation vac-
cination against invasive pneumococcal disease should be
offered to all patients, as well as a yearly vaccination for
seasonal influenza. Immunoglobulin substitution should be
considered in patients with hypogammaglobulinaemia
(IgG <6 g/l) and related infections. Prophylaxis against
varicella zoster virus and pneumocystis pneumonia are part
of most immuno/chemotherapy schemes.
If the heart is affected, heart failure with preserved ejection
fraction (HFpEF), with diastolic dysfunction and its con-
sequences, is the main clinical issue. Fluid retention leads
to dyspnoea, leg oedema, ascites, weight gain and loss of
appetite. Furthermore, high left ventricular filling pressure,
together with structural alterations in the atrium, increas-
es the likelihood for atrial fibrillation and thus thromboem-
bolic stroke. Besides atrial fibrillation, amyloid deposits
may lead to heart blocks and ventricular tachycardia, the
latter being an important contributor to mortality. Tradi-
tional heart failure therapy such as beta-blockers or an-
giotensin converting-enzyme inhibitors are not well tol-
erated and may even worsen clinical symptoms and
outcome. Diuretics are the cornerstone of heart failure
management in amyloidosis patients; however, doses must
be titrated carefully. As a result of the altered pressure/
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volume relationship in the “stiff” heart with severe dias-
tolic dysfunction, “over diuresis” might lead to profound
hypotension, whereas “under diuresis” worsens dyspnoea
and increases the risk for cardiac decompensations. An-
tiarrhythmic therapy should be restricted to amiodarone,
rate control with a beta-blocker is an option, but heart rate
should not be lowered too much (cardiac output in pa-
tients with cardiac amyloidosis depends on heart rate, be-
cause stroke volume is fixed owing to amyloid deposits).
Regular screening for atrial fibrillation is mandatory in pa-
tients with cardiac amyloidosis, and all patients with atri-
al fibrillation should receive oral anticoagulation, irrespec-
tive of the CHA2DS2-VASc score, given the very high risk
for thromboembolic events. The SAN experts recommend
that selected patients with an atrial mechanical dysfunc-
tion and a restrictive filling pattern (severe diastolic dys-
function), after careful evaluation of bleeding risk, receive
anticoagulation, irrespective of whether atrial fibrillation
is present or not [79]. Particular attention should be giv-
en to ventricular arrhythmias with their risk for sudden
cardiac death. Although an implantable cardioverter defib-
rillator may provide life-saving treatments, its long-term
benefit on mortality has not been proven in cardiac amyloi-
dosis and should be made on an individual basis in selected
cases [80, 81].
In patients with renal AL-amyloidosis and proteinuria, the
SAN does not recommend anti-proteinuric treatment with
renin-angiotensin-aldosterone system blocking agents. It is
unknown whether they provide a benefit, and they might
be harmful in patients with co-existing autonomic dysfunc-
tion and cardiac amyloidosis. Nephrotoxic drugs should be
avoided whenever possible.
Doxycycline, an antibiotic that has been used as a prophy-
laxis in the ASCT [82] setting, has been shown to have a
fibril-stabilising effect in a transgenic mouse model [83].
Currently, a phase III study is comparing doxycycline with
standard supportive therapy in newly diagnosed patients
undergoing bortezomib-based therapy (NCT03474485).
The addition of doxycycline to induction therapy can be
considered. Patients should be instructed about phototox-
icity, sunscreen SPF 50 should be applied. The results
of a randomised trial comparing epigallocatechin-3-gallate
(EGCG, “green tea”) to placebo conducted in Heidelberg
and presented at the ISA 2018 conference in Kumamoto
did not show benefit in the EGCG group.
Amyloid-targeted therapies
In recent years, research also focused on the clearance of
already deposited amyloid fibrils. There have been three
antibodies under development, but so far none of them has
shown clinical efficacy leading to commercialisation. The
antibody NEOD001 showed promising results in a phase
I/II trial [84], but further development was halted when a
phase IIb trial did not meet its primary and secondary end-
points [85]. The entire phase III programme was then dis-
continued, based on futility analysis [86]. Carboxy-pyrro-
lidinyl-hexanoyl-pyrrolidine-carboxylate (CPHPC), a
small molecule that binds to serum amyloid P in the plas-
ma in combination with an anti-SAP antibody [87] to re-
move the deposited amyloid in the tissue, was able to show
clearance of amyloid in 15 patients. The phase II trial had
some major safety problems and had to be halted [88]. The
third antibody under development is called 11-1F4. The re-
sults from the phase I trial are promising, showing early or-
gan response [89]. A phase II trial is planned.
It is worth noting that therapies that target protein aggre-
gation are not trivial. For instance, dissolution of fibrils
may lead to formation of soluble oligomers, which may
have a negative effect if these species are responsible for
toxicity. It is therefore crucial to develop compounds that
do not generally target protein aggregates but specifically
decrease the concentration of the most toxic species. This
specific targeting requires a fundamental understanding of
the molecular mechanisms responsible for amyloid forma-
tion and dissolution, as well as of the relationship between
aggregation and toxicity. This is an area where close inter-
actions between academia and medical doctors are crucial
to advance the field [90].
Solid organ transplantation
The goal of treatment is to reduce/eliminate toxic FLC pro-
duction in order to achieve organ response and eventual-
ly prolong survival [45]. Even among patients achieving
haematological response, there is a significant proportion
in whom organ damage is irreversible at the time of diag-
nosis or will continue to deteriorate owing to residual pro-
duction of toxic immunoglobulins [91], sometimes even
undetected by standard methods. For years, the role of sol-
id organ transplant as an option in end-stage organ failure
for patients with AL-amyloidosis was questioned, main-
ly because of the lack of effective plasma cell-directed
therapy, complications with the allograft and organ donor
shortage [92]. With the introduction of highly effective
therapies and improvement in the management of trans-
plant-related complications and supportive care, the per-
ception changed. Recently published data show that out-
come of organ transplantation in AL-amyloidosis in
patients with predominantly single organ involvement is
good (5-year survival with kidney transplants 67–86% [82,
93], heart transplants 60–77% [94–98]). The main limita-
tion is the retrospective nature of the data. Efforts should
be made to establish specific selection criteria for solid or-
gan transplantation, which should be guided by a multidis-
ciplinary team in specialised centres.
Conclusion
There have been recent major improvements in the man-
agement of AL-amyloidosis with improved outcome. De-
spite some recent disappointments and setbacks in the field
of amyloid-targeting therapies, mortality has decreased
over time and especially new plasma cell-directed thera-
pies allow long-term control of the disease with good qual-
ity of life. We still face the challenge of early diagnosis
and allowing access to the more effective treatment op-
tions. Expert groups such as the SAN might help in in-
creasing awareness of the disease and guidance in tailored
treatment for healthcare providers not as familiar with the
disease. Furthermore, the SAN should take the role of
providing an interface between academia, pharmaceutical
companies, regulatory agencies and health insurance to op-
timise patient treatment with respect to financial resources
of the Swiss healthcare system.
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